Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of ...

A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Pfizer has won the ...

Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...

Diabetes and obesity care were a key growth driver, however the company lowered its expectations for growth, citing prescription trends, competition and pricing pressure. A slew of headwinds has ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

Novo launches rival bid to Pfizer Metsera calls Novo bid 'superior' Metsera says Novo bid values company at around $9 billion Pfizer calls Novo bid 'reckless', bad for competition Novo Nordisk, the ...

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish ...